MCID: LKM005
MIFTS: 33

Leukemia, T-Cell, Chronic

Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Leukemia, T-Cell, Chronic

MalaCards integrated aliases for Leukemia, T-Cell, Chronic:

Name: Leukemia, T-Cell, Chronic 20 70
Chronic T-Cell Leukemia 20
Leukemia, T-Cell 70
T-Cell Leukemia 20

Classifications:



External Ids:

UMLS 70 C0023492 C0023494

Summaries for Leukemia, T-Cell, Chronic

MalaCards based summary : Leukemia, T-Cell, Chronic, also known as chronic t-cell leukemia, is related to adult t-cell leukemia and t-cell lymphoblastic leukemia/lymphoma. The drugs Zidovudine and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include t cells, myeloid and bone marrow.

Related Diseases for Leukemia, T-Cell, Chronic

Diseases in the Adult T-Cell Leukemia family:

Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, T-Cell, Chronic

Diseases related to Leukemia, T-Cell, Chronic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 540)
# Related Disease Score Top Affiliating Genes
1 adult t-cell leukemia 12.1
2 t-cell lymphoblastic leukemia/lymphoma 11.8
3 human t-cell leukemia virus type 1 11.8
4 human t-cell leukemia virus type 2 11.5
5 t-cell adult acute lymphocytic leukemia 11.5
6 t-cell prolymphocytic leukemia 11.5
7 htlv-1 associated myelopathy/tropical spastic paraparesis 11.4
8 myelopathy, htlv-1-associated 11.3
9 tropical spastic paraparesis 11.3
10 leukemia 11.3
11 t-cell acute lymphoblastic leukemia 11.3
12 pediatric t-cell leukemia 11.3
13 human t-cell leukemia virus type 3 11.3
14 lymphoma 11.2
15 n syndrome 11.1
16 retrovirus-associated myelopathy 11.1
17 spastic paraparesis 11.0
18 leukemia, acute lymphoblastic 10.8
19 precursor t-cell acute lymphoblastic leukemia 10.8
20 human immunodeficiency virus type 1 10.8
21 severe combined immunodeficiency 10.7
22 leukemia, chronic lymphocytic 10.7
23 mycosis fungoides 10.7
24 acquired immunodeficiency syndrome 10.7
25 peripheral t-cell lymphoma 10.6
26 cutaneous t cell lymphoma 10.6
27 lymphoproliferative syndrome 10.6
28 graft-versus-host disease 10.6
29 b-cell lymphoma 10.6
30 strongyloidiasis 10.5
31 uveitis 10.5
32 exanthem 10.5
33 splenomegaly 10.5
34 hairy cell leukemia 10.5
35 bone resorption disease 10.5
36 acute leukemia 10.5
37 lymphoma, hodgkin, classic 10.5
38 retinoblastoma 10.5
39 immune deficiency disease 10.5
40 chromosomal triplication 10.5
41 lymphoma, non-hodgkin, familial 10.4
42 neutropenia 10.4
43 stomatitis 10.4
44 hypereosinophilic syndrome 10.4
45 lymphosarcoma 10.4
46 anaplastic large cell lymphoma 10.4
47 combined immunodeficiency 10.4
48 prolymphocytic leukemia 10.4
49 acute graft versus host disease 10.4
50 pancytopenia 10.4

Graphical network of the top 20 diseases related to Leukemia, T-Cell, Chronic:



Diseases related to Leukemia, T-Cell, Chronic

Symptoms & Phenotypes for Leukemia, T-Cell, Chronic

Drugs & Therapeutics for Leukemia, T-Cell, Chronic

Drugs for Leukemia, T-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4 30516-87-1 35370
2
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4
Daclizumab Investigational, Withdrawn Phase 4 152923-56-3
5 Reverse Transcriptase Inhibitors Phase 4
6 Anti-Retroviral Agents Phase 4
7 interferons Phase 4
8 Interferon alpha-2 Phase 4
9 Interferon-alpha Phase 4
10 Anti-HIV Agents Phase 4
11 Neurotransmitter Agents Phase 4
12 Psychotropic Drugs Phase 4
13 Anticonvulsants Phase 4
14
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
15
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
16
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
17
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
18
Cytarabine Approved, Investigational Phase 2, Phase 3 147-94-4 6253
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
20
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
21
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
22
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
23
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
24
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
25
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
26
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
27
Aclarubicin Investigational Phase 3 57576-44-0 451415
28 Adjuvants, Immunologic Phase 3
29
Liposomal doxorubicin Phase 2, Phase 3 31703
30 Tubulin Modulators Phase 2, Phase 3
31 Hormone Antagonists Phase 2, Phase 3
32 glucocorticoids Phase 2, Phase 3
33 Antimitotic Agents Phase 2, Phase 3
34 Hormones Phase 2, Phase 3
35 Antineoplastic Agents, Hormonal Phase 2, Phase 3
36 Dermatologic Agents Phase 2, Phase 3
37 Gastrointestinal Agents Phase 2, Phase 3
38 Antiemetics Phase 2, Phase 3
39
Homoharringtonine Phase 3 285033
40 Folic Acid Antagonists Phase 2, Phase 3
41
alemtuzumab Approved, Investigational Phase 2 216503-57-0
42
Vindesine Approved, Investigational Phase 2 59917-39-4, 53643-48-4 40839
43
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
44
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
45
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
46
Melphalan Approved Phase 2 148-82-3 4053 460612
47
Triamcinolone Approved, Vet_approved Phase 1, Phase 2 124-94-7 31307
48
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
49
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
50
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563

Interventional clinical trials:

(show top 50) (show all 139)
# Name Status NCT ID Phase Drugs
1 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
3 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Unknown status NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
5 Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
6 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
7 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
8 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Unknown status NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
9 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
10 Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease) Completed NCT01173887 Phase 2 VCAP/AMP/VECP(mLSG15)
11 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
12 Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma Completed NCT00920790 Phase 2
13 Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Completed NCT01626664 Phase 2 Pralatrexate;gemcitabine plus oxaliplatin;DHAP
14 Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
15 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
16 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
17 A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
18 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
19 Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma Completed NCT00081874 Phase 1, Phase 2 RAD001
20 Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
21 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
22 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
23 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
24 Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma Completed NCT00082888 Phase 2 Tipifarnib
25 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
26 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
27 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
28 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
29 Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
30 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
31 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
32 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
33 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
34 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
35 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
36 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
37 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
38 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
39 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
40 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
41 A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma Completed NCT00611208 Phase 2
42 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
43 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
44 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
45 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
46 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
47 PHASE I/II STUDY OF TAC-EXPRESSING ADULT T-CELL LEUKEMIA (ATL) WITH YTTRIUM-90 (90Y)-RADIOLABELED HUMANIZED ANTI-TAC AND CALCIUM-DTPA Completed NCT00019227 Phase 1, Phase 2 pentetic acid calcium
48 Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Malignancies Recruiting NCT04689659 Phase 2
49 A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Recruiting NCT02737046 Phase 2 Belinostat;Zidovudine;Interferon-Alfa-2b;Pegylated Interferon-Alfa-2b
50 A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Prednisone

Search NIH Clinical Center for Leukemia, T-Cell, Chronic

Genetic Tests for Leukemia, T-Cell, Chronic

Anatomical Context for Leukemia, T-Cell, Chronic

MalaCards organs/tissues related to Leukemia, T-Cell, Chronic:

40
T Cells, Myeloid, Bone Marrow, Endothelial, B Cells, Liver, Lymph Node

Publications for Leukemia, T-Cell, Chronic

Articles related to Leukemia, T-Cell, Chronic:

(show top 50) (show all 8873)
# Title Authors PMID Year
1
Successful treatment with famciclovir for varicella zoster virus infection resistant to acyclovir. 61
33358593 2021
2
Overview on coinfection of HTLV-1 and tuberculosis: Mini-review. 61
33681477 2021
3
A case of vesiculobullous adult T-cell leukemia/lymphoma with a poor prognosis. 61
33580894 2021
4
Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy. 61
32959166 2021
5
Direct single-molecule imaging for diagnostic and blood screening assays. 61
33790018 2021
6
Analysis of a within-host HIV/HTLV-I co-infection model with immunity. 61
33157165 2021
7
Comprehensive genomic analysis identifying heterogeneity in peripheral T-cell lymphoma. 61
33576080 2021
8
HTLV-1 viral oncoprotein HBZ contributes to the enhancement of HAX-1 stability by impairing the ubiquitination pathway. 61
32893878 2021
9
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma. 61
33301622 2021
10
Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. 61
32555298 2021
11
Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. 61
33779474 2021
12
Cutaneous adult T-cell leukemia/lymphoma with granulomatous reaction. 61
33772842 2021
13
Chronic cystoisosporiasis in an immunocompetent adult: A case report. 61
33725845 2021
14
Correction to: Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma. 61
33730358 2021
15
Author Correction: 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy. 61
33723351 2021
16
Facile synthesis of Au/ZnO/Ag nanoparticles using Glechoma hederacea L. extract, and their activity against leukemia. 61
33683457 2021
17
Metachronous Wilms Tumor, Glioblastoma, and T-cell Leukemia in an Child With Constitutional Mismatch Repair Deficiency syndrome due to Novel Mutation in MSH6 (c.2590G>T). 61
31815888 2021
18
Tocilizumab has no direct effect on cell lines infected with human T-cell leukemia virus type 1. 61
33745335 2021
19
Loss of FADD and Caspases Affects the Response of T-Cell Leukemia Jurkat Cells to Anti-Cancer Drugs. 61
33800107 2021
20
Genetic profile of adult T-cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV-1 strains. 61
33426772 2021
21
Short-term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax-specific CTL response in adult T-cell leukemia patients. 61
33410215 2021
22
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) versus adult T-cell leukemia/lymphoma (ATLL). 61
33757561 2021
23
Anti-human T-cell leukemia virus type 1 (HTLV-1) antibody assays in cerebrospinal fluid for the diagnosis of HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
33658267 2021
24
In silico identification of epitope-based vaccine candidates against HTLV-1. 61
33648421 2021
25
Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy-intolerant lymphoma patients. 61
33656972 2021
26
Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries. 61
33125593 2021
27
NF-κB-induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. 61
33649200 2021
28
A regulatory element in the 3'-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia. 61
33197296 2021
29
Issues of infant feeding for postnatal prevention of human T-cell leukemia/lymphoma virus type-1 mother-to-child transmission. 61
32574414 2021
30
Adult T-cell Leukemia/Lymphoma with Gastrointestinal Involvement. 61
33551411 2021
31
Adult T-cell leukemia/lymphoma with pagetoid reticulosis-like skin lesions. 61
33559154 2021
32
Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma. 61
32973330 2021
33
RLTPR Q575E: A novel recurrent gain-of-function mutation in patients with adult T-cell leukemia/lymphoma. 61
33098696 2021
34
Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma. 61
33594654 2021
35
XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. 61
33563902 2021
36
Adult T-cell leukemia-lymphoma as a viral disease: Subtypes based on viral aspects. 61
33630351 2021
37
Overexpression of aberrant Wnt5a and its effect on acquisition of malignant phenotypes in adult T-cell leukemia/lymphoma (ATL) cells. 61
33603066 2021
38
Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T cell leukemia. 61
33626865 2021
39
Loss of interleukin-10 activates innate immunity to eradicate adult T cell leukemia initiating cells. 61
33567810 2021
40
Acute Pulmonary Graft-Versus-Host Disease in a Patient with Adult T-cell Leukemia-Lymphoma Diagnosed by a Cryobiopsy. 61
33583892 2021
41
Frequency of Infectious Mortality at the End of Induction Chemotherapy in Acute Lymphoblastic Leukemia and Lymphoma Patients: Findings From a Tertiary Care Cancer Center. 61
33717747 2021
42
Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells. 61
32914311 2021
43
Estimation of the window period of human T-cell leukemia virus type 1 and 2 tests by a lookback study of seroconverters among Japanese voluntary blood donors. 61
33368334 2021
44
An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. 61
32835825 2021
45
Human T-cell leukemia virus type 1 infection among Japanese immigrants and their descendants living in Southeast Brazil: A call for preventive and control responses. 61
33544713 2021
46
Extracellular vesicles from HTLV-1 infected cells modulate target cells and viral spread. 61
33622348 2021
47
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. 61
32054656 2021
48
In Vivo Tumorigenesis, Osteolytic Sarcomas, and Tumorigenic Cell Lines from Transgenic Mice Expressing the Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Viral Oncogene. 61
33181139 2021
49
Novel Mutations in a Lethal Case of Lymphomatous Adult T Cell Lymphoma with Cryptic Myocardial Involvement. 61
33562071 2021
50
Ficus pumila L. improves the prognosis of patients infected with HTLV-1, an RNA virus. 61
33573641 2021

Variations for Leukemia, T-Cell, Chronic

Expression for Leukemia, T-Cell, Chronic

Search GEO for disease gene expression data for Leukemia, T-Cell, Chronic.

Pathways for Leukemia, T-Cell, Chronic

GO Terms for Leukemia, T-Cell, Chronic

Sources for Leukemia, T-Cell, Chronic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....